Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Intuitive Surgical Inc., long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial ratios for the company exhibit distinct trends over the analyzed quarterly periods, reflecting changes in asset utilization and equity efficiency.
- Net Fixed Asset Turnover
- This ratio shows a consistent decline from 2.86 in the first quarter of 2021 to a low of 1.77 by the third quarter of 2024, with a slight recovery to 1.87 by the third quarter of 2025. The downward trend indicates a gradual decrease in the efficiency with which the company generates revenue from its net fixed assets. This could suggest increased investment in fixed assets without a proportional increase in sales, or a reduction in operational efficiency related to fixed assets.
- Total Asset Turnover
- The total asset turnover ratio exhibits an overall upward trend, rising from 0.39 in the first quarter of 2021 to 0.50 by the third quarter of 2025. Although there are minor fluctuations, the general movement suggests improved utilization of all company assets to generate sales. This improvement may be indicative of better management of asset base or more effective deployment of resources contributing to revenue generation.
- Equity Turnover
- Equity turnover increases from 0.45 in early 2021 to a peak of 0.57 towards the close of the period examined in 2025. This increasing ratio reflects enhanced efficiency in generating sales from shareholders' equity. There are some periods of slight decline or stabilization, but the general direction is upward, highlighting possible improvements in capital management or profitability relative to equity.
In summary, while the company appears to be experiencing a decline in revenue generation from net fixed assets, it demonstrates improved overall asset and equity turnover. This suggests a shift towards more effective utilization of its broader asset base and equity capital over the observed time frame.
Net Fixed Asset Turnover
Intuitive Surgical Inc., net fixed asset turnover calculation (quarterly data)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenue | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | ||||||
| Property, plant, and equipment, net | 5,150,900) | 4,985,300) | 4,799,000) | 4,646,600) | 4,433,000) | 4,116,800) | 3,799,600) | 3,537,600) | 3,077,000) | 2,830,800) | 2,580,200) | 2,374,200) | 2,243,700) | 2,109,300) | 1,968,200) | 1,876,400) | 1,737,900) | 1,651,200) | 1,592,900) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Net fixed asset turnover1 | 1.87 | 1.83 | 1.82 | 1.80 | 1.77 | 1.84 | 1.93 | 2.01 | 2.23 | 2.35 | 2.49 | 2.62 | 2.73 | 2.83 | 3.00 | 3.04 | 3.16 | 3.13 | 2.86 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 3.81 | 3.78 | 3.87 | 3.94 | 3.88 | 3.98 | 3.99 | 3.95 | 4.18 | 4.26 | 4.47 | 4.76 | 5.18 | 5.17 | 5.00 | 4.81 | 4.79 | 4.56 | 4.23 | ||||||
| Elevance Health Inc. | 41.50 | 40.49 | 39.35 | 37.66 | 38.33 | 38.30 | 38.32 | 39.05 | 39.41 | 36.19 | 36.14 | 36.07 | 36.22 | 36.17 | 35.81 | 34.94 | 34.54 | 34.17 | 34.94 | ||||||
| Medtronic PLC | 5.04 | 5.13 | 5.19 | 5.28 | 5.54 | 5.57 | 5.57 | 5.61 | 5.66 | 5.82 | 5.88 | 5.85 | 6.05 | 6.13 | 6.12 | 5.77 | 5.56 | 5.64 | 5.72 | ||||||
| UnitedHealth Group Inc. | 38.75 | 38.22 | 37.72 | 37.44 | 38.37 | 38.90 | 35.98 | 32.10 | 32.18 | 31.60 | 31.35 | 31.81 | 33.07 | 32.33 | 32.16 | 31.81 | 31.77 | 30.94 | 30.76 | ||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Net fixed asset turnover
= (RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025
+ RevenueQ4 2024)
÷ Property, plant, and equipment, net
= (2,505,100 + 2,440,000 + 2,253,400 + 2,413,500)
÷ 5,150,900 = 1.87
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue demonstrates a generally upward trajectory over the observed periods. Starting at approximately $1.29 billion in March 2021, it increases steadily with minor fluctuations, reaching around $2.51 billion by September 2025. This reflects sustained growth across the quarters, with notable acceleration in the latter periods, especially from December 2024 onward.
- Property, Plant, and Equipment (PP&E) Trends
- The net value of property, plant, and equipment shows a continuous and substantial increase throughout the periods. Beginning at approximately $1.59 billion in March 2021, it expands consistently each quarter, culminating near $5.15 billion by September 2025. This sharp rise suggests significant capital investment and asset base expansion over time.
- Net Fixed Asset Turnover Ratio Trends
- The net fixed asset turnover ratio declines steadily over the timeframe. Initially at 2.86 in March 2021, the ratio decreases progressively to 1.87 by September 2025. This indicates that revenue generated per dollar of net fixed assets is diminishing, which may reflect either increasing investment in assets that have yet to proportionally contribute to revenue or possible inefficiencies in asset utilization relative to revenue growth.
- Overall Insights
- The company exhibits strong revenue growth accompanied by significant increases in fixed asset investment. However, the declining fixed asset turnover ratio signals a reduction in efficiency of asset use to generate revenue. This pattern suggests that while the company is expanding its asset base aggressively, the returns from these investments are not scaling at the same pace, highlighting a potential area for monitoring operational effectiveness and capital allocation.
Total Asset Turnover
Intuitive Surgical Inc., total asset turnover calculation (quarterly data)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenue | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | ||||||
| Total assets | 19,351,800) | 20,163,200) | 19,220,400) | 18,743,200) | 17,743,400) | 16,649,900) | 15,828,000) | 15,441,500) | 14,712,700) | 13,903,300) | 13,053,200) | 12,974,000) | 13,260,800) | 13,705,200) | 13,678,400) | 13,555,000) | 12,934,600) | 12,297,000) | 11,540,400) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Total asset turnover1 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.45 | 0.46 | 0.46 | 0.47 | 0.48 | 0.49 | 0.48 | 0.46 | 0.44 | 0.43 | 0.42 | 0.42 | 0.42 | 0.39 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.52 | 0.51 | 0.52 | 0.52 | 0.55 | 0.56 | 0.56 | 0.55 | 0.55 | 0.55 | 0.56 | 0.59 | 0.62 | 0.61 | 0.60 | 0.57 | 0.57 | 0.55 | 0.51 | ||||||
| Elevance Health Inc. | 1.57 | 1.54 | 1.52 | 1.50 | 1.48 | 1.51 | 1.52 | 1.56 | 1.52 | 1.51 | 1.46 | 1.51 | 1.48 | 1.47 | 1.42 | 1.41 | 1.35 | 1.33 | 1.29 | ||||||
| Medtronic PLC | 0.37 | 0.37 | 0.36 | 0.36 | 0.36 | 0.35 | 0.35 | 0.34 | 0.33 | 0.33 | 0.35 | 0.35 | 0.35 | 0.35 | 0.34 | 0.32 | 0.29 | 0.29 | 0.30 | ||||||
| UnitedHealth Group Inc. | 1.36 | 1.35 | 1.31 | 1.32 | 1.30 | 1.33 | 1.32 | 1.34 | 1.26 | 1.23 | 1.18 | 1.31 | 1.29 | 1.32 | 1.33 | 1.34 | 1.30 | 1.29 | 1.27 | ||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Total asset turnover
= (RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025
+ RevenueQ4 2024)
÷ Total assets
= (2,505,100 + 2,440,000 + 2,253,400 + 2,413,500)
÷ 19,351,800 = 0.50
2 Click competitor name to see calculations.
- Revenue Trends
- Revenue demonstrates a general upward trend over the periods analyzed, rising from approximately $1.29 billion in March 2021 to over $2.5 billion by September 2025. There are consistent increases observed each year, with notable acceleration from late 2023 onward. The most significant quarterly increase occurs between December 2024 and March 2025, where revenue surges sharply from about $2.41 billion to $2.53 billion. This indicates steady growth in the company’s core operations, reflecting enhanced sales performance or expansion activities.
- Total Assets Trends
- Total assets steadily expand from around $11.54 billion in March 2021, reaching a peak near $20.16 billion in June 2025. This suggests ongoing asset accumulation possibly due to investments, acquisitions, or capital expenditures. However, there is a slight decline after this peak, dropping to about $19.35 billion by September 2025. The overall trajectory shows substantial asset growth over the period, though the minor decrease toward the end may signal asset divestitures, depreciation outpacing acquisitions, or other balance sheet adjustments.
- Total Asset Turnover Analysis
- The total asset turnover ratio exhibits a moderate improvement from 0.39 in the first quarter of 2021 to 0.5 by September 2025, indicating enhanced efficiency in utilizing assets to generate revenue. The ratio peaks at 0.5 in the latest quarter, after showing incremental increases through the intermediate periods. A peak ratio above 0.45 starting in late 2022 suggests sustained operational efficiency gains despite significant asset growth. This balance implies effective asset management and an ability to maintain or increase revenue generation relative to the asset base.
- Overall Financial Insights
- The analysis reveals strong revenue growth accompanied by steady asset base expansion and increasingly efficient use of assets. The company appears to successfully leverage its asset investments into higher sales, as indicated by the improving asset turnover ratio over the nearly five-year period. Minor fluctuations near the end of the timeline in total assets might warrant closer evaluation, but the overall trend indicates sound financial health with positive growth momentum and operational efficiency improvements.
Equity Turnover
Intuitive Surgical Inc., equity turnover calculation (quarterly data)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenue | 2,505,100) | 2,440,000) | 2,253,400) | 2,413,500) | 2,038,100) | 2,009,900) | 1,890,600) | 1,928,300) | 1,743,700) | 1,755,900) | 1,696,200) | 1,655,000) | 1,557,400) | 1,522,100) | 1,487,700) | 1,550,700) | 1,403,300) | 1,464,000) | 1,292,100) | ||||||
| Total Intuitive Surgical, Inc. stockholders’ equity | 16,929,700) | 17,845,700) | 17,106,400) | 16,433,700) | 15,583,300) | 14,708,300) | 13,962,600) | 13,307,600) | 12,539,000) | 11,879,100) | 11,217,700) | 11,041,900) | 11,515,400) | 12,023,000) | 12,102,300) | 11,901,100) | 11,410,900) | 10,837,500) | 10,153,500) | ||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Equity turnover1 | 0.57 | 0.51 | 0.51 | 0.51 | 0.50 | 0.51 | 0.52 | 0.54 | 0.55 | 0.56 | 0.57 | 0.56 | 0.53 | 0.50 | 0.49 | 0.48 | 0.48 | 0.48 | 0.45 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | 0.86 | 0.85 | 0.87 | 0.88 | 1.04 | 1.04 | 1.04 | 1.04 | 1.07 | 1.08 | 1.12 | 1.19 | 1.26 | 1.25 | 1.26 | 1.20 | 1.23 | 1.19 | 1.11 | ||||||
| Elevance Health Inc. | 4.40 | 4.30 | 4.27 | 4.24 | 3.94 | 4.04 | 4.20 | 4.33 | 4.36 | 4.31 | 4.27 | 4.29 | 4.22 | 4.13 | 3.97 | 3.80 | 3.71 | 3.65 | 3.65 | ||||||
| Medtronic PLC | 0.67 | 0.68 | 0.68 | 0.64 | 0.62 | 0.62 | 0.62 | 0.61 | 0.60 | 0.59 | 0.59 | 0.60 | 0.60 | 0.61 | 0.61 | 0.59 | 0.55 | 0.56 | 0.56 | ||||||
| UnitedHealth Group Inc. | 4.49 | 4.41 | 4.26 | 4.26 | 4.12 | 4.27 | 4.33 | 4.14 | 4.22 | 4.19 | 4.10 | 4.14 | 4.19 | 4.18 | 4.06 | 3.98 | 3.95 | 3.92 | 3.94 | ||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Equity turnover
= (RevenueQ3 2025
+ RevenueQ2 2025
+ RevenueQ1 2025
+ RevenueQ4 2024)
÷ Total Intuitive Surgical, Inc. stockholders’ equity
= (2,505,100 + 2,440,000 + 2,253,400 + 2,413,500)
÷ 16,929,700 = 0.57
2 Click competitor name to see calculations.
The financial data of the company over the analyzed quarterly periods reveals several notable trends in revenue, stockholders’ equity, and equity turnover ratio.
- Revenue
- The company's revenue demonstrates a generally upward trajectory from March 2021 to December 2025. Initial revenue stood at approximately $1.29 billion in March 2021 and experienced fluctuations with periods of growth, reaching about $2.51 billion by September 2025. This indicates a significant overall increase in the company's sales over the five-year period, with some seasonal or cyclical variations seen between quarters.
- Total Intuitive Surgical, Inc. Stockholders’ Equity
- Stockholders’ equity shows a steady increase from around $10.15 billion in March 2021 to a peak exceeding $17.8 billion in June 2025, followed by a slight decline to about $16.93 billion in September 2025. This steady growth over the years underlines the company’s ability to build equity, suggesting retained earnings, share issuances, or other equity-enhancing activities. The minor decrease in the last quarter signals a potential one-time adjustment or change in capital structure that might warrant further examination.
- Equity Turnover Ratio
- The equity turnover ratio, which measures how efficiently the company is using its equity to generate revenue, trends upward from 0.45 in March 2021 to a peak near 0.57 in September 2025. There are intermediate fluctuations, with the ratio reaching around 0.56 towards the end of 2022 and maintaining generally high levels thereafter. This indicates improving efficiency in utilizing equity base for revenue generation, although some periods show small declines, suggesting temporary shifts in operational effectiveness or capital deployment.
In summary, the company experienced robust revenue growth accompanied by a consistent increase in stockholders' equity over the observed timeline. The upward trend in the equity turnover ratio reflects improved efficiency in converting equity into sales, supporting the positive operational momentum. However, minor fluctuations in equity and turnover toward the end of the period suggest areas that may merit closer monitoring to sustain growth and efficiency.